Immediate-early protein 2 (IE2) (IE2)

The Cytomegalovirus UL122 protein, commonly referred to as Immediate-Early 2 (IE2) or IE86, is a master regulatory protein essential for the replication and pathogenesis of Human Cytomegalovirus (HCMV) [1, 2]. As one of the first proteins synthesized during the viral life cycle, IE2 acts as a potent transcriptional transactivator that initiates the expression of early and late viral genes required for DNA synthesis and virion assembly [2, 12]. It also functions as a transcriptional repressor of its own promoter, the major immediate-early promoter (MIEP), to precisely control the timing of viral gene expression [2, 19]. Beyond its direct role in the viral cycle, IE2 extensively manipulates the host cell environment by inducing cell cycle progression into the S phase, inhibiting apoptosis, and modulating immune signaling to facilitate viral persistence and evasion [10, 11, 14]. Because IE2 is indispensable for viral replication, it has been identified as a high-priority therapeutic target [10, 13]. The antisense oligonucleotide fomivirsen was the first drug designed to target this protein by binding to UL122 mRNA and preventing its translation, thereby arresting the viral life cycle at the earliest stage [10, 13]. While current clinical management of CMV often relies on DNA polymerase inhibitors, targeting IE2 remains a critical area of research for developing therapies that can prevent the broad dysregulation of host cell functions caused by early viral proteins [10, 18].

Other names

IE2IE86IE2-86pp86Regulatory protein IE2UL122 proteinViral transcription factor IE2

Antisense oligonucleotide-mediated inhibition of viral mRNA translation